7:41 PM
 | 
Dec 03, 2012
 |  BC Extra  |  Clinical News

Sanofi to present first Phase II data for SAR302503 for myelofibrosis

Sanofi (Euronext:SAN; NYSE:SNY) will present on Sunday the first Phase II data for myelofibrosis (MF) compound SAR302503 (formerly TG101348), which the pharma gained through its 2010 acquisition of TargeGen Inc. In an abstract released ahead of the American Society of Hematology...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >